于万晴, 陈超, 杨亚玺, 智英, 周兵. 靶向泛素特异性蛋白酶7的药物研究进展J. 药学学报, 2025, 60(8): 2453-2465. DOI: 10.16438/j.0513-4870.2024-1048
引用本文: 于万晴, 陈超, 杨亚玺, 智英, 周兵. 靶向泛素特异性蛋白酶7的药物研究进展J. 药学学报, 2025, 60(8): 2453-2465. DOI: 10.16438/j.0513-4870.2024-1048
YU Wan-qing, CHEN Chao, YANG Ya-xi, ZHI Ying, ZHOU Bing. Advances in drug research targeting ubiquitin-specific protease 7J. Acta Pharmaceutica Sinica, 2025, 60(8): 2453-2465. DOI: 10.16438/j.0513-4870.2024-1048
Citation: YU Wan-qing, CHEN Chao, YANG Ya-xi, ZHI Ying, ZHOU Bing. Advances in drug research targeting ubiquitin-specific protease 7J. Acta Pharmaceutica Sinica, 2025, 60(8): 2453-2465. DOI: 10.16438/j.0513-4870.2024-1048

靶向泛素特异性蛋白酶7的药物研究进展

Advances in drug research targeting ubiquitin-specific protease 7

  • 摘要: 泛素特异性蛋白酶7 (ubiquitin-specific protease 7, USP7) 是去泛素化酶家族中研究较为广泛的成员之一, 能调节细胞内多种蛋白的活性和功能。USP7与癌症的发生发展密切相关, 使其成为一个极具潜力的药物治疗靶点。但目前尚未有靶向USP7的药物被批准进入临床试验, 以USP7为靶点的药物开发仍然需要深入的研究。本文综述了USP7的结构、功能及以USP7为靶点的药物研究进展。

     

    Abstract: Ubiquitin-specific protease 7 (USP7) is one of the more widely studied members of the deubiquitinating enzyme family, which regulates the activity and function of a variety of proteins in cells. USP7 is closely associated with the tumor progression, which makes USP7 a highly promising target for drug therapy. However, no drug targeting USP7 has yet been approved for clinical trials, thus the development of drug targeting USP7 still requires in-depth research. This article reviews the structure and function of USP7 and the progress of drug research targeting USP7.

     

/

返回文章
返回